This study is currently recruiting participants.
Number
85-I-0127
Sponsoring Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Recruitment Detail
Type: Participants currently recruited/enrolled Gender: Male & Female Min Age: 3 Years Max Age: 99 Years
Referral Letter Required
No
Population Exclusion(s)
None
Keywords
Taenia Solium; Neurocysticercosis; Tapeworm; Natural History
Recruitment Keyword(s)
Condition(s)
Cysticercosis
Investigational Drug(s)
Investigational Device(s)
Intervention(s)
Supporting Site
National Institute of Allergy and Infectious Diseases
Patients with suspected or confirmed cysticercosis may be eligible for this study. Participants will be hospitalized for 2 to 3 weeks and will take either praziquantel or albendazole by mouth for 2 weeks. They may receive a corticosteroid to lessen the side effects of the drug therapy. Patients will be evaluated with medically indicated tests and procedures that may include:
- Blood tests.
- X-rays of the head and long bones.
- Electroencephalogram - recording of the electrical activity of the brain
- Lumbar puncture (spinal tap) - examination of the cerebrospinal fluid that bathes the brain and spinal cord. For this procedure, a local anesthetic is given and a needle is inserted in the space between the bones (vertebrae) in the lower back. About 2 tablespoons of fluid is collected through the needle.
- Eye examination.
- Magnetic resonance imaging (MRI) to examine the brain. MRI uses a strong magnetic field and radio waves instead of X-rays to demonstrate structural and chemical changes in the brain. During the scan, the patient lies on a table in a narrow cylinder (the scanner). He or she can speak with a staff member via an intercom system at all times during the procedure.
- Computed tomography (CT) to examine the brain. CT can be done from different angles and allows the doctor to view the brain in small sections in 3-dimensions. The patient lies on a table with the head positioned in the CT scanner.
Some of the tests may be repeated on the last day of therapy and at 3 and 6 months or longer after therapy.
--Back to Top--
INCLUSION CRITERIA: 1. Patients ages 3 to 99 years. 2. Patients with proven or likely neurocysticercosis. 3. Willingness (of participant or legally authorized representative [LAR]) to sign consent and comply with study requirements. EXCLUSION CRITERIA: Not applicable.
1. Patients ages 3 to 99 years.
2. Patients with proven or likely neurocysticercosis.
3. Willingness (of participant or legally authorized representative [LAR]) to sign consent and comply with study requirements.
EXCLUSION CRITERIA:
Not applicable.
Principal Investigator
Referral Contact
For more information: